Journal for ImmunoTherapy of Cancer (Nov 2023)

1167 Prediction of first-in-human dose for HPN536, a T-cell engager targeting mesothelin: MABEL vs mechanistic translational PK/RO/PA modeling

  • Oleg Demin,
  • Dmitry Shchelokov

DOI
https://doi.org/10.1136/jitc-2023-SITC2023.1167
Journal volume & issue
Vol. 11, no. Suppl 1

Abstract

Read online

No abstracts available.